Alle Studien
Aktiv, aber nicht rekrutierendPHASE3INTERVENTIONELL

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

This research study is investigating a new medication, Remibrutinib, for adults who have Generalized Myasthenia Gravis. The main aim is to understand if Remibrutinib is effective at helping with the symptoms of this condition, how safe it is, and whether people can tolerate it well. Participants will either receive Remibrutinib or a placebo (a dummy medicine that looks the same but has no active ingredient), in addition to their current, stable treatments. This will be done in a way that neither the patient nor their doctor knows who is getting which treatment at first. The study hopes to gather important information that could help improve future treatment options for Myasthenia Gravis.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE3
Sponsor
Novartis Pharma
Einschreibeziel
180
Starten
07 Feb 2025
Geschätzte Fertigstellung
26 Feb 2033

Worum geht es in dieser Studie?

This study is about an illness called Generalized Myasthenia Gravis, which is a long-term condition that causes muscle weakness. It's looking into a new medicine called Remibrutinib. The main goal is to find out if this medicine can help improve symptoms, if it's safe to use, and if people find it easy to take, especially when they're already on their usual treatments.

To do this, some adult patients with Generalized Myasthenia Gravis will receive the new medicine, Remibrutinib, while others will get a placebo. A placebo looks just like the real medicine but contains no active ingredient. This is a common way to test new medicines, as it helps researchers see if any improvements are truly due to the new drug or something else. Neither the patients nor their doctors will know who is receiving which treatment during the first part of the study; this is called 'double-blind'.

Later, everyone will have the chance to take Remibrutinib. The study aims to involve around 180 people and split them into two groups. By carefully comparing the groups, experts hope to learn a lot about Remibrutinib and whether it could become a helpful new treatment option for people living with Generalized Myasthenia Gravis.

Wichtige Erkenntnisse

  • This study is testing a new medicine (Remibrutinib) for Generalized Myasthenia Gravis.
  • It aims to see how well it works and if it's safe.
  • You would continue your existing Myasthenia Gravis treatments.
  • Participants will either receive Remibrutinib or a dummy drug (placebo) at first.
  • The study could last for several years, with regular check-ups.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

This study is looking for adults aged between 18 and 75 who have been diagnosed with Generalized Myasthenia Gravis. Your doctor will need to confirm you have a certain level of Myasthenia Gravis symptoms and are unlikely to need breathing support during the study.

You'll also need to have had specific antibody tests that confirm your Myasthenia Gravis, or show you don't have these antibodies. Your symptoms should include a certain level of daily activity difficulties, with at least half of these difficulties not related to your eyes. You must also be on a steady dose of your current Myasthenia Gravis treatments and be able to swallow the study medication safely.

There are also some reasons why you might not be able to join. For example, if you've recently had certain treatments like IV immunoglobulins, plasma exchange, or specific therapies such as rituximab, eculizumab, or efgartigimod within certain timeframes before the study. Also, if you've had surgery to remove your thymus gland in the last six months or plan to have one, you wouldn't be able to join. Women who could become pregnant must be using effective contraception throughout the study and for a week afterwards.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you an adult between 18 and 75 years old?
  2. Do you have a confirmed diagnosis of Generalized Myasthenia Gravis?
  3. Are your Myasthenia Gravis symptoms mostly affecting parts of your body other than your eyes?
  4. Are you currently on a stable dose of your usual Myasthenia Gravis treatments?
  5. Can you safely swallow medications, as checked by your doctor?
  6. Have you avoided certain other Myasthenia Gravis treatments (like IVIg/PLEX, rituximab, eculizumab, etc.) within specific recent timeframes?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, it will be split into two main parts. For the first six months, you will either receive Remibrutinib or a placebo, and neither you nor your doctors will know which one. This period involves regular visits to the clinic for assessments and to check how you're feeling and if the treatment is helping.

After these first six months, if you wish to continue, you could then enter an 'open-label' part of the study. This means everyone will receive Remibrutinib, and everyone will know they are receiving the active drug. This longer part could last for up to five years. Throughout the study, you'll have appointments to review your health, check for any side effects, and monitor your Myasthenia Gravis symptoms. The study medication will need to be swallowed, and your ability to do so will be assessed.

Potenzielle Risiken und Vorteile

Taking part in a study like this might offer a potential benefit if Remibrutinib helps improve your Myasthenia Gravis symptoms more than your current treatment or the placebo. However, there's also a chance you might experience side effects from the new medicine, or that it might not help your symptoms. The research team will carefully monitor you for any changes in your health. Remember, joining any clinical study is always voluntary, and you have the right to withdraw at any time without explaining your reasons, and this will not affect your future medical care.

Locations (120)

  • Neuromuscular Research Center
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten
  • Honor Health Research Institute
    Verifizierte Postleitzahl
    Scottsdale, Vereinigte Staaten
  • Fullerton Neuro and Headache Ctr
    Verifizierte Postleitzahl
    Fullerton, Vereinigte Staaten
  • University Of Southern California
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten
  • Kalifornisches Pazifik-Medizinzentrum
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten
  • Medstar Washington Hospital Center
    Verifizierte Postleitzahl
    Washington D.C., Vereinigte Staaten
  • SFM Clinical Research LLC
    Verifizierte Postleitzahl
    Boca Raton, Vereinigte Staaten
  • Homestead Assoc In Research Inc
    Verifizierte Postleitzahl
    Homestead, United States
  • Neurology Associates PA
    Verifizierte Postleitzahl
    Maitland, Vereinigte Staaten
  • AdventHealth
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten
  • Neurological Services of Orlando PA
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten
  • University of Chicago Medical Centr
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten

Häufige Fragen

What is Generalized Myasthenia Gravis?

It's a long-term condition that causes muscle weakness throughout the body.

What is Remibrutinib?

It's a new medicine being tested to see if it can help people with Myasthenia Gravis.

Was ist ein 'Placebo'?

A placebo is a dummy medicine that looks like the real drug but contains no active ingredients. It's used for comparison.

Werde ich wissen, ob ich das echte Medikament oder das Placebo erhalte?

For the first six months, neither you nor your doctor will know. After that, everyone will get the active medicine.

Wie lange wird die Studie dauern?

The main part is six months, with an option to continue for up to five years.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.